• Portugal

    EXMceuticals Portugal has already obtained the authorization for cannabis research and development from INFARMED, the Portuguese National Authority of Medicines and Health Products, in November 2019. This crucial scientific license, currently unique in Portugal, allowed EXMceuticals to take a leap forward in its European operations by being able to import, research and refine cannabinoids and cannabis-based ingredients inside the European Union, for R&D purposes. EXMceuticals's fully operational R&D laboratory in Portugal will now develop cannabis-based formulations for products and operate as a pilot-scale refinery for the transformation of cannabis-based ingredients.

    EXM now has a massive opportunity and a clear path to add a commercial and industrial license for cannabis to our existing R&D license. The company has already secured an existing industrial facility close to Lisbon, which is perfect for the purpose of creating a substantial extraction, purification and refining operation.



    The priority for the Company in 1H 2020 will be the fitting-out and equipping of this facility to create a pharmaceutical-grade factory that will be designed to EU-GMP standards. Once finished and commercially licensed this facility will permit the supply and export of extremely pure cannabis ingredients across the EU and beyond, all under the aegis of the Portuguese medicines regulator (INFARMED).

    EXM's existing R&D center in Lisbon, Portugal inside TecLabs, a well-recognized start-up incubator from Faculdade de Ciências, Universidade de Lisboa, is fully equipped and staffed by experienced scientists (microbiologists, biochemists and geneticists). At the moment, the lab is submitting 2 main research projects focusing on cannabis-based therapeutics and cannabinoids extraction-purification processes.


    Building for the R&D Refining Facilities 1.jpg

    These projects are supported by Portugal 2020, a Framework Program between Portugal and the European Commission that brings together five European Structural and Investment Funds. EXM’s R&D staff are also working with several companies from several sectors ranging from wellness to Pharmaceutical, with a clear goal to create formulations for products to go to market.

  • Uganda

    EXM through its local subsidiary Prime Ranchers Limited started a pilot-scale project of its operations in Uganda.

    Therefore, EXM will be able to cultivate cannabis on a largescale, extract pharmaceutical, therapeutical and nutraceutical grade cannabinoid ingredients and export the produced ingredients, including CBD.

    The license also allows the importation of high-quality cannabis seeds developed in Europe in order to provide the seed-stock for cultivation operations.

    2,000 hectares (4,940 acres) of agricultural land is available.

    • Parcels of which will be put into production sequentially.
    • Initial planting will consist of 100 hectares (247 acres) and the first plant harvest will occur within 4 months.
    • 2,000 sq.m. (21,500 sq. ft.) of lab, extraction and material handling facilities are available.

    Extraction facilities have already been built, commissioned and inspected by relevant Ugandan regulatory authorities.

    Uganda Extractor

    All the relevant utilities such as power generation, water and waste management, which are required by the Project, are fully budgeted, funded and planned by the company.

    EXM is committed to having a tangibly positive local impact and close relationships are being built with the Ugandan agriculture education institutions. The Company fully intends to foster local expertise as well as to help create technical jobs locally.

  • Malawi

    EXM is in the process of acquiring MM Ltd, an agro-processing business in the Republic of Malawi.

    MM Ltd has :

    • 280ha (682 acres) of fully drip-irrigated farms
    • A state of the art 4ha (10 acres) greenhouse nursery capable of growing up to 700,000 plants; it is drip irrigated, enclosed and secured to protect plants from natural elements
    • A 10,000 m2 (107,640 ft2) processing facility and a green field site with access to ~1700ha (4,200 acres) of land
    • A long-term lease of an additional ~1700ha (4,200 acres) of land for further farming expansion, 450ha (1,112 acres) of which has been certified as organic

    MM Farm Aerial Picture 1.jpeg

    All farms are located nearby of on the shores of Lake Malawi, a large freshwater resource from which excellent quality irrigation water is available all year round.


    The factory is approximately 25km (15.5 miles) from the farms

    • It has passed audits and technical approval to supply a number of global and regional clients
    • Approximately 2,000 m2 (21,528 ft2) of the factory is warehouse space and there is significant room for expansion of cannabis ingredients production and CO2 extraction capabilities
    • There is an office block, medical facilities and canteen on the factory site


    Weather in Salima is exceptional for cannabis cultivation. Climate is tropical with rainfall being less in winter than in summer. The average annual rainfall varies between 800 and 1,200mm per annum, with the wettest months being December to March. The temperatures range between a minimum average of 20°C and a maximum average of 35°C, with low humidity of around 60%.


    MM Ltd provides an excellent platform for EXM to further expand its cannabis extracted ingredients production strategy, with the possibility to access to an additional ~120ha (296 acres) of irrigated land.


  • Canada

    EXMceuticals has an MOU with GFR Pharma Inc in Vancouver’s suburb of Coquitlam. GFR Pharma and EXM has established a joint venture company. GFR Pharma is a pre-eminent full-service contract manufacturer, packager and formulation expert of superior quality tablet, capsule, powder, and liquid natural health products for the Canada and the U.S.